- Home
- SEVN vs ENLV Comparison
SEVN vs ENLV Comparison
Compare SEVN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | ENLV |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 149.0M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SEVN | ENLV |
|---|---|---|
| Price | $7.66 | $1.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.50 | ★ $20.00 |
| AVG Volume (30 Days) | 174.2K | ★ 239.9K |
| Earning Date | 04-28-2026 | 05-29-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $39.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $0.43 |
| 52 Week High | $11.15 | $7.64 |
Technical Indicators
Market Signals| Indicator | SEVN | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 38.91 |
| Support Level | $7.37 | $0.77 |
| Resistance Level | $8.81 | $1.81 |
| Average True Range (ATR) | 0.20 | 0.35 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 36.05 | 2.91 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.